Latest setback for Dato-DXd comes after disappointing results in lung cancer treatment earlier this month
Results offer hope of progress in combating bladder tumours and some forms of breast cancer
GSK and AstraZeneca plan final trials to upgrade propellants that cause much of the sector’s carbon footprint
Failure to reach statistical significance sets back effort to build oncology portfolio
Police reportedly probing five current and former employees over infringement of data privacy laws
The first in an FT series looking at the new energy behind the fight for cancer cures
British pharmaceutical company unhappy at chancellor Rachel Reeves’ plan to cut state aid for project
Merseyside plant had been offered £65mn for redevelopment but review looks to reduce figure to £40mn
Drugmaker has benefited from its bet on developing a portfolio of cancer drugs
Nice blames cost for not recommending Enhertu, which has helped patients in clinical trials live longer
Pascal Soriot criticises decision to block breast cancer drug in England as FTSE 100 group raises profit outlook
Pharma group believes successful medicines from its clinical trials could generate $20bn in revenue by 2030
Anglo-Swedish drugmaker targets $80bn in revenue by 2030
Anglo-Swedish drugmaker to produce targeted chemotherapy drug at facility
Anglo-Swedish drugmaker says availability of newer vaccines hit demand for jab
Continent’s drugmakers need to pay up to attract and retain talent, says Pascal Soriot
Michel Demaré in FT hits out at ISS and Glass Lewis for applying ‘double standards’ after they opposed CEO pay package
Double standards over pay do serious harm to our competitiveness in the war for talent
Almost 36 per cent of shareholders voted against a £1.8mn rise for the pharma group’s boss
GQG Partners argues that pharma group has performed strongly under long-serving chief
UK pharma group’s chief has a fresh challenge — persuading investors that its best days are not behind it
Shareholder advisory groups say potential £18.7mn payout is excessive
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
